Status:

UNKNOWN

Cardiovascular Effects of Selective I(f)-Channel Blockade

Lead Sponsor:

Hannover Medical School

Collaborating Sponsors:

Charite University, Berlin, Germany

Conditions:

Postural Orthostatic Tachycardia Syndrome

Eligibility:

MALE

18-40 years

Phase:

PHASE2

Brief Summary

The study compares three treatment modalities in a human model of Postural orthostatic tachycardia syndrome (POTS): beta-blockers, I(f)-blockers, and placebo.

Detailed Description

Elevated heart rate may lead to cardiac disease in the long-term. Therefore, drugs lowering heart rate are useful. Beta-blockers are an established treatment modality. They not only lower heart rate b...

Eligibility Criteria

Inclusion

  • healthy male
  • age 18-40 years
  • BMI: 18-30 kg/m²
  • arterial blood pressure \<=160/100 mm Hg
  • co-operativity
  • voluntariness

Exclusion

  • conditions in which treatment might be ineffective or insecure
  • co-medication within the last 4 weeks
  • participation in another clinical trial within the last 4 weeks
  • unability to understand the study's aim
  • drug or alcohol abuse
  • secondary hypertension
  • creatinine \> 130 μM (1.47 mg/dl)
  • GOT/GPT \> 2 times normal
  • GGT \> 3 times normal
  • contraindications against reboxetine, beta-blocker, ivabradine
  • asthma, psoriasis
  • diabetes
  • heart failure (NYHA III or IV)
  • coronary artery disease
  • peripheral occlusive disease
  • cerebrovascular disease
  • ventricular extrasystoles (Lown III-V)
  • atrial fibrillation
  • resting heart rate \<60/min
  • neurologic/psychiatric disorder
  • pulmonary hypertension
  • dysthyroid metabolism

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2010

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00865917

Start Date

November 1 2008

End Date

December 1 2010

Last Update

March 19 2009

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Franz-Volhard Centrum für Klinische Forschung

Berlin, Germany, 13125

2

Medizinische Hochschule Hannover

Hanover, Germany, 30625